SKINBIO THERAP LS-01
Research SKINBIO THERAP LS-01 (5KW) on Bullrun: market cap EUR 32.14M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker5KW
- ExchangeF
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 32.14M
- Financial periodFY2025
- RevenueEUR 4.64M
- Revenue growth283.7%
- Net income-EUR 696.25K
- Free cash flow-EUR 1.39M
- Gross margin61.6%
Valuation Snapshot
latest market cap is EUR 32.14M.
About SKINBIO THERAP LS-01
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development.
Frequently asked questions
What is SKINBIO THERAP LS-01's market cap?
SKINBIO THERAP LS-01's market capitalization is EUR 32.14M.
What does SKINBIO THERAP LS-01 do?
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally.